|Capital commitment from BGF (million)||Fund size (million)||% BGF||Investment date||Sector focus||Stage of investment|
|Fortino Capital II Growth NV||€ 20||€ 242||8,3%||20/11/2019||ICT & Technology||Late stage venture|
|Smartfin Capital II Comm.V.||€ 25||€ 239||10,5%||20/11/2019||ICT & Technology||Late stage venture|
|Sofindev V Comm.V.||€ 20||€ 170||11,8%||23/12/2019||Generalistic||Buy-out|
|Gilde Healthcare V||€ 15||€ 416||3,6%||17/03/2020||Life sciences||Late stage venture|
|Forbion GO I||€ 20||€ 185||10,8%||01/07/2020||Life sciences||Late stage venture|
|TOTAL||€ 100||€ 1252|
Fortino Capital II Growth NV
Fortino invests in ambitious scale-ups and more mature business (SMEs) which are facing typical challenges regarding go-to-market, innovation and organizational design and talent management. Fortino supports CEOs and their management teams to scale internationally.
+32 2 669 10 50
Smartfin Capital II Comm.V.
Smartfin provides replacement and expansion capital to European growth companies that display the potential for significant value creation in fast growing market segments. Smartfin combines financial, operational and entrepreneurial experience supporting its portfolio companies in their growth ambitions.
Jürgen Ingels & Bart Luyten
+32 15 28 78 80
Sofindev V Comm.V.
Sofindev is an independent private equity firm investing in small and medium sized enterprises in Belgium since 1991. Sofindev invests in buyout and growth capital in profitable Belgian SME’s to support their growth strategy.
Eric van Droogenbroeck & Jan Camerlynck
Gilde Healthcare V is a €416 million venture and growth capital fund and targets growth opportunities in healthcare sectors including digital health, medtech and therapeutics, both in Europe and North America.
Forbion Growth Opportunities I
Forbion is a leading venture capital firm that works closely with entrepreneurs to build life sciences companies with technologies and products designed to transform people’s lives. The fund approaches the market through three strategies and focuses on growth capital, pre-IPO financing and the support of undervalued assets.